Northern Trust’s Cognition Therapeutics CGTX Stock Holding History

Northern Trust’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$205K	Buy	178,202 +9,516	+6%	+$11.3K	﹤0.01%	3927
2026 Q1	$128K	Sell	168,686 -25,628	-13%	-$29.8K	﹤0.01%	4053
2025 Q4	$262K	Buy	194,314 +49,073	+34%	+$79.7K	﹤0.01%	3885
2025 Q3	$196K	Buy	145,241 +97,756	+206%	+$133K	﹤0.01%	3990
2025 Q2	$14.7K	Hold	47,485	–	–	﹤0.01%	4362
2025 Q1	$20K	Hold	47,485	–	–	﹤0.01%	4339
2024 Q4	$33.3K	Hold	47,485	–	–	﹤0.01%	4321
2024 Q3	$22.3K	Hold	47,485	–	–	﹤0.01%	4325
2024 Q2	$78.8K	Hold	47,485	–	–	﹤0.01%	4101
2024 Q1	$86.4K	Buy	47,485 +16,763	+55%	+$34.6K	﹤0.01%	4117
2023 Q4	$56.8K	Hold	30,722	–	–	﹤0.01%	4216
2023 Q3	$44.2K	Hold	30,722	–	–	﹤0.01%	4195
2023 Q2	$56.2K	Buy	30,722 +1,538	+5%	+$3.25K	﹤0.01%	4197
2023 Q1	$57.8K	Hold	29,184	–	–	﹤0.01%	4229
2022 Q4	$61.3K	Buy	29,184 +15,068	+107%	+$30.4K	﹤0.01%	4229
2022 Q3	$27K	Buy	+14,116	New	+$29.4K	﹤0.01%	4483

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Northern Trust's CGTX Position: Q2 2026 in Review

Northern Trust increased its Cognition Therapeutics (CGTX) stake by 5.6% in Q2 2026, buying an estimated $11.3K and bringing the position to 178,202 shares worth $205K. The position accounts for ﹤0.01% of the portfolio, ranked #3927.

Northern Trust first reported a position in CGTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $262K in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

Northern Trust held 178,202 shares of Cognition Therapeutics worth $205K as of Q2 2026.
Northern Trust bought 9,516 Cognition Therapeutics shares in Q2 2026, an estimated $11.3K.
Cognition Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3927 holding.
Northern Trust first reported a position in Cognition Therapeutics in Q3 2022 and has held it in 16 quarters since.
Northern Trust's Cognition Therapeutics position peaked at $262K in Q4 2025.
66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.